A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Active, not recruiting · NCT06198751 · Registry updated 2025-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-08-19 | NCT06198751 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chongqing Cancer Hospital | Chongqing | China | 16 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 13 |
| Fujian Cancer Hospital | Fuzhou | China | 109 |
| Guizhou Cancer Hospital | Guiyang | China | 1 |
| Harbin Medical University Cancer Hospital | Harbin | China | 2 |
| Hunan Cancer Hospital | Changsha | China | 123 |
| Liaoning Cancer Hospital & Institute | Shenyang | China | 10 |